Car-Engineered Nk Cells; a Promising Therapeutic Option for Treatment of Hematological Malignancies

Car-Engineered Nk Cells; a Promising Therapeutic Option for Treatment of Hematological Malignancies Publisher Pubmed

Marofi F¹ ; Saleh MM² ; Rahman HS^{3, 4} ; Suksatan W⁵ ; Algazally ME⁶ ; Abdelbasset WK^{7, 8} ; Thangavelu L⁹ ; Yumashev AV¹⁰ ; Hassanzadeh A¹¹ ; Yazdanifar M¹² ; Motavalli R¹³ ; Pathak Y^{14, 15} ; Naimi A¹⁶ ; Baradaran B¹ Show All Authors

Marofi F¹
Saleh MM²
Rahman HS^{3, 4}
Suksatan W⁵
Algazally ME⁶
Abdelbasset WK^{7, 8}
Thangavelu L⁹
Yumashev AV¹⁰
Hassanzadeh A¹¹
Yazdanifar M¹²
Motavalli R¹³
Pathak Y^{14, 15}
Naimi A¹⁶
Baradaran B¹
Nikoo M¹⁷
Khiavi FM¹⁸

Show Affiliations

1. Immunology Research Center (IRC), Tabriz University of Medical Sciences, Tabriz, Iran
2. Department of Biophysics, College of Applied Science, University of Anbar, Ramadi, Iraq
3. College of Medicine, University of Sulaimani, Sulaymaniyah, Iraq
4. Department of Medical Laboratory Sciences, Komar University of Science and Technology, Chaq-Chaq Qularaise, Sulaimaniyah, Iraq
5. Faculty of Nursing, HRH Princess Chulabhorn College of Medical Science, Chulabhorn Royal Academy, Bangkok, 10210, Thailand
6. College of Medicine, Al-Ameed University, Karbala, Iraq
7. Department of Health and Rehabilitation Sciences, College of Applied Medical Sciences, Prince Sattam bin Abdulaziz University, Al Kharj, Saudi Arabia
8. Department of Physical Therapy, Kasr Al-Aini Hospital, Cairo University, Giza, Egypt
9. Department of Pharmacology, Saveetha Dental College and Hospital, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, India
10. Sechenov First Moscow State Medical University, Moscow, Russian Federation
11. Department of Applied Cell Sciences, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
12. Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics, Stanford University School of Medicine, Palo Alto, CA, United States
13. Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
14. Professor and Associate Dean for Faculty Affairs, Taneja College of Pharmacy, University of South Florida, Tampa, FL, United States
15. Faculty of Pharmacy, Airlangga University, Surabaya, Indonesia
16. Cellular and Molecular Research Center, Sabzevar University of Medical Sciences, Sabzevar, Iran
17. Department of Immunology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran
18. Department of Virology, Pasteur Institute of Iran, Tehran, Iran

Source: Stem Cell Research and Therapy Published:2021

Abstract

Adoptive cell therapy has received a great deal of interest in the treatment of advanced cancers that are resistant to traditional therapy. The tremendous success of chimeric antigen receptor (CAR)-engineered T (CAR-T) cells in the treatment of cancer, especially hematological cancers, has exposed CAR’s potential. However, the toxicity and significant limitations of CAR-T cell immunotherapy prompted research into other immune cells as potential candidates for CAR engineering. NK cells are a major component of the innate immune system, especially for tumor immunosurveillance. They have a higher propensity for immunotherapy in hematologic malignancies because they can detect and eliminate cancerous cells more effectively. In comparison to CAR-T cells, CAR-NK cells can be prepared from allogeneic donors and are safer with a lower chance of cytokine release syndrome and graft-versus-host disease, as well as being a more efficient antitumor activity with high efficiency for off-the-shelf production. Moreover, CAR-NK cells may be modified to target various antigens while also increasing their expansion and survival in vivo. Extensive preclinical research has shown that NK cells can be effectively engineered to express CARs with substantial cytotoxic activity against both hematological and solid tumors, establishing evidence for potential clinical trials of CAR-NK cells. In this review, we discuss recent advances in CAR-NK cell engineering in a variety of hematological malignancies, as well as the main challenges that influence the outcomes of CAR-NK cell-based tumor immunotherapies. © 2021, The Author(s).

Related Docs

View other Related Docs

1. Car-Nk Cells for Haematological Cancers, Best Practice and Research: Clinical Haematology (2025)

2. Preclinical Studies of Chimeric Antigen Receptor-Modified Natural Killer Cells in Cancer Immunotherapy: A Review, Expert Opinion on Biological Therapy (2022)

3. The Tricks for Fighting Against Cancer Using Car Nk Cells: A Review, Molecular and Cellular Probes (2022)

4. Chimeric Antigen Receptor-Natural Killer Cells: A Promising Sword Against Insidious Tumor Cells, Human Cell (2023)

5. Car-Nk Cells: A Promising Cellular Immunotherapy in Lymphoma, Expert Opinion on Biological Therapy (2023)

6. Advances in Natural Killer Cell Therapies for Breast Cancer, Immunology and Cell Biology (2023)

7. Natural Killer Cells and Acute Myeloid Leukemia: Promises and Challenges, Cancer Immunology# Immunotherapy (2022)

8. Car-Nk Cell: A New Paradigm in Tumor Immunotherapy, Frontiers in Oncology (2021)

Experts (# of related papers)

View all Related Experts

Nima Rezaei (21)

Hamid Reza Mirzaei (10)

Style	Citing Format
MLA	Marofi F, et al.. "Car-Engineered Nk Cells; a Promising Therapeutic Option for Treatment of Hematological Malignancies." Stem Cell Research and Therapy, vol. 12, no. 1, 2021, pp. -.
APA	Marofi F, Saleh MM, Rahman HS, Suksatan W, Algazally ME, Abdelbasset WK, Thangavelu L, Yumashev AV, Hassanzadeh A, Yazdanifar M, Motavalli R, Pathak Y, Naimi A, Baradaran B, Nikoo M, Khiavi FM (2021). Car-Engineered Nk Cells; a Promising Therapeutic Option for Treatment of Hematological Malignancies. Stem Cell Research and Therapy, 12(1), -.
Chicago	Marofi F, Saleh MM, Rahman HS, Suksatan W, Algazally ME, Abdelbasset WK, Thangavelu L, et al.. "Car-Engineered Nk Cells; a Promising Therapeutic Option for Treatment of Hematological Malignancies." Stem Cell Research and Therapy 12, no. 1 (2021): -.
Harvard	Marofi F et al. (2021) 'Car-Engineered Nk Cells; a Promising Therapeutic Option for Treatment of Hematological Malignancies', Stem Cell Research and Therapy, 12(1), pp. -.
Vancouver	Marofi F, Saleh MM, Rahman HS, Suksatan W, Algazally ME, Abdelbasset WK, et al.. Car-Engineered Nk Cells; a Promising Therapeutic Option for Treatment of Hematological Malignancies. Stem Cell Research and Therapy. 2021;12(1):-.
BibTex	@article{ author = {Marofi F and Saleh MM and Rahman HS and Suksatan W and Algazally ME and Abdelbasset WK and Thangavelu L and Yumashev AV and Hassanzadeh A and Yazdanifar M and Motavalli R and Pathak Y and Naimi A and Baradaran B and Nikoo M and Khiavi FM}, title = {Car-Engineered Nk Cells; a Promising Therapeutic Option for Treatment of Hematological Malignancies}, journal = {Stem Cell Research and Therapy}, volume = {12}, number = {1}, pages = {-}, year = {2021} }
RIS	TY - JOUR AU - Marofi F AU - Saleh MM AU - Rahman HS AU - Suksatan W AU - Algazally ME AU - Abdelbasset WK AU - Thangavelu L AU - Yumashev AV AU - Hassanzadeh A AU - Yazdanifar M AU - Motavalli R AU - Pathak Y AU - Naimi A AU - Baradaran B AU - Nikoo M AU - Khiavi FM TI - Car-Engineered Nk Cells; a Promising Therapeutic Option for Treatment of Hematological Malignancies JO - Stem Cell Research and Therapy VL - 12 IS - 1 SP - EP - PY - 2021 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract